Eli Lilly Person - Search News

From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Business Insider · 3d

Eli Lilly obesity drug trial participants losing ‘too much weight,’ STAT reports

In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen

Quartz on MSN · 3d

Eli Lilly wants to use its weight loss drug windfall to fight Alzheimer's and hearing loss

The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the world. Now, the pharma giant wants to reinvest its success with weight-loss meds into tackling some of the world’s toughest health challenges.

Hosted on MSN · 17d

Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared. The company's quarterly earnings topped Wall Street estimates,

3don MSN

Eli Lilly aims to invest in ‘big problems hiding in plain sight' using obesity windfall

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

13d

Lilly Sells $6.5 Billion of Bonds for Cancer Drug Purchase

Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...

Seeking Alpha3d

Lilly's next obesity drug serves up dramatic weight loss -- and side effects (updated)

Editor's note: This story was updated at 1225p ET on Feb. 21 with comment from Eli Lilly. Several individuals enrolled in a phase 3 trial for Eli Lilly's (NYSE:LLY) next-generation obesity ...

17don MSN

Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results